Tretinoin
- Generic Name
- Tretinoin
- Brand Names
- Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 302-79-4
- Unique Ingredient Identifier
- 5688UTC01R
- Background
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...
- Indication
Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...
- Associated Conditions
- Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
- Associated Therapies
- -
Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 204
- Registration Number
- NCT00867672
- Locations
- 🇩🇪
Vivantes Klinikum Neukölln, Berlin, Germany
🇩🇪Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
🇩🇪Klinikum der Technischen Universität Aachen, Aachen, Germany
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 106
- Registration Number
- NCT00866918
- Locations
- 🇺🇸
Overlook Hospital, Summit, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 20
- Registration Number
- NCT00842907
- Locations
- 🇧🇷
Federal University of Sao Paulo, Sao Paulo, SP, Brazil
Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 163
- Registration Number
- NCT00835198
APL93: Timing of CxT and Role of Maintenance
- Conditions
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2008-01-24
- Target Recruit Count
- 576
- Registration Number
- NCT00599937
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 78
- Registration Number
- NCT00551460
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸Saint Louis University Cancer Center, Saint Louis, Missouri, United States
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2011-12-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00533169
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00528450
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Raghu Nandan, M.D., Inc
- Target Recruit Count
- 39
- Registration Number
- NCT00514293
- Locations
- 🇺🇸
R. Nandan M.D. Incorporated, Lakewood, California, United States
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
- Conditions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT00504764
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital de Mataró, Mataró, Barcelona, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.